Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!
Attractive stocks have exceptional fundamentals. In the case of Pharmanutra S.p.A. (BIT:PHN), there's is a company with impressive financial health as well as a excellent growth outlook. Below is a brief commentary on these key aspects. For those interested in digger a bit deeper into my commentary, read the full report on Pharmanutra here.
Excellent balance sheet with reasonable growth potential
PHN’s cash-generating ability is outstanding, with analysts expecting its operating cash flows to flourish by 68% in the upcoming year. This underlies the notable 28% return on equity over the next few years leading up to 2022. PHN's strong financial health means that all of its upcoming liability payments are able to be met by its current cash and short-term investment holdings. This indicates that PHN has sufficient cash flows and proper cash management in place, which is a key determinant of the company’s health. PHN's has produced operating cash levels of 1.2x total debt over the past year, which implies that PHN's management has put its borrowings into good use by generating enough cash to cover a sufficient portion of borrowings.
Next Steps:
For Pharmanutra, there are three fundamental aspects you should look at:
- Historical Performance: What has PHN's returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Valuation: What is PHN worth today? Is the stock undervalued, even when its growth outlook is factored into its intrinsic value? The intrinsic value infographic in our free research report helps visualize whether PHN is currently mispriced by the market.
- Other Attractive Alternatives : Are there other well-rounded stocks you could be holding instead of PHN? Explore our interactive list of stocks with large potential to get an idea of what else is out there you may be missing!
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.
About BIT:PHN
Pharmanutra
A pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally.
High growth potential with solid track record.
Similar Companies
Market Insights
Weekly Picks
Early mover in a fast growing industry. Likely to experience share price volatility as they scale

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Moderation and Stabilisation: HOLD: Fair Price based on a 4-year Cycle is $12.08
Recently Updated Narratives
Airbnb Stock: Platform Growth in a World of Saturation and Scrutiny
Adobe Stock: AI-Fueled ARR Growth Pushes Guidance Higher, But Cost Pressures Loom
Thomson Reuters Stock: When Legal Intelligence Becomes Mission-Critical Infrastructure
Popular Narratives

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

The AI Infrastructure Giant Grows Into Its Valuation
Trending Discussion
